Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that VEOZAH™ (fezolinetant), its first-in-class, targeted, non-hormonal treatment for moderate to severe ...

Protein supplements are wildly popular, but CR’s tests of 23 products found that more than two-thirds of them contain more ...

APQC Study warns of looming "Great Retirement" crisis and highlights the role of AI and Knowledge Management to mitigate risk.